Search tool

Displaying 211 - 220 of 994

National report 2014: Serbia

This report has been produced by a national working group within the European Union financed EMCDDA-IPA project, 'Preparation of IPA Beneficiaries for their participation with the EMCDDA'. It describes the overall picture...

Pregnancy and opioid use: strategies for treatment

Illicit opioid consumption during pregnancy brings with it the risk of an increase in obstetric complications for the mother and a range of potential dangers for the child, both before and after...

Risk Assessment Report of a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)

This report presents the data and findings of the risk assessment on the new psychoactive substance, MT-45, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and...

Computer-assisted and online data collection in general population surveys

The aim of the present report is to collect information from a literature review on computer-assisted interviewing and online data collection in general population surveys. It evaluates the pros and cons of...

Drugnet Europe 87

In this issue: EMCDDA scientific paper award 2014 | New report examines residential treatment for drug use in Europe | Exploring therapeutic communities for treating addictions | First European conference on addictive...

EMCDDA–Europol Joint Report on a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (‘MT-45’)

In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been accumulated to...

Annual accounts 2013

In accordance with Article 76 of the Financial Regulation applicable to the EMCDDA, the accounts of the EMCDDA shall comprise: 'The financial statements of the EMCDDA and the reports on implementation of...

EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA

This report presents the key activities performed by the EMCDDA and Europol in 2013, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the...

EMCDDA–Europol Joint Report on a new psychoactive substance: 4,4'-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine)

In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4'-DMAR). The two organisations concluded that sufficient information had been...

A year in review: Highlights from the EMCDDA’s General Report of Activities 2013

The series 'A year in review' contains the essence of the EMCDDA's General Report of Activities. It is designed to provide interested audiences with a brief, four-page summary of the agency’s achievements...